Science Park

Oxford, United States

Science Park

Oxford, United States

Time filter

Source Type

Outre Interxion, le PoP sera interconnecté avec Digital Realty, SURFsara et l'Institut national néerlandais de physique subatomique (Nikhef). Les consommateurs auront accès au réseau IP mondial de NTT Com et à ses services de transit IP, ses solutions Ethernet Couche 2 et ses services de protection contre les attaques DDoS. « NTT Com se consacre à anticiper la demande des utilisateurs et a identifié l'Amsterdam Science Park comme un pôle de classe mondiale pour la recherche, l'innovation et l'entrepreneuriat. Nous sommes ravis de soutenir une communauté aussi dynamique et à la pointe de la technologie », a commenté Toby Russell, directeur des ventes pour NTT Europe. Dans le cadre de ce soutien, NTT Com parraine également MORE-IP, un événement de réseautage pour le secteur d'Internet se déroulant à Amsterdam. Celui-ci est animé par l'organisation à but non lucratif AMS-IX (Amsterdam Internet Exchange), l'un des plus importants points d'échange Internet au monde, comptant des sites dans la région étendue d'Amsterdam ainsi qu'au Science Park. « Les Pays-Bas jouent un rôle stratégique dans l'infrastructure numérique mondiale, dont la densité et la capacité grandissent. Avec cette expansion, NTT Com apporte une contribution importante à son évolution à la fois aux Pays-Bas et dans le monde entier », a déclaré Jesse Robbers, CCO d'AMS-IX. NTT Communications propose des services de conseil, d'architecture, de sécurité et de Cloud dans le but d'optimiser les environnements informatiques des entreprises. Ces offres sont soutenues par l'infrastructure mondiale de la société, notamment un réseau IP mondial de première catégorie, le réseau VPN Arcstar Universal One(TM) présent dans 196 pays/régions et plus de 140 centres de données sécurisés. Les solutions de NTT Communications tirent profit des ressources mondiales des sociétés du groupe NTT dont Dimension Data, NTT DOCOMO et NTT DATA. Constamment classé parmi les meilleurs réseaux à travers le monde, le Global IP Network (réseau IP mondial) de première catégorie de NTT Com couvre l'Amérique du Nord et du Sud, l'Asie, l'Europe et l'Océanie, et fournit le meilleur environnement possible pour le transfert de contenu, de données et de vidéo via un numéro de système autonome unique (AS 2914). NTT Com est l'un des plus grands grossistes mondiaux d'IP et le fournisseur numéro un en Asie selon les tout derniers classements des grossistes Dyn Wholesale Rankings.


News Article | May 22, 2017
Site: www.prnewswire.com

Der neue PoP befindet sich im Gebäude des Rechenzentrums von Interxion (ehemals Vancis) im Amsterdam Science Park. Es handelt sich dabei um den dritten Standort von NTT Com in dieser Stadt. Der neue PoP verdeutlicht das Engagement des Unternehmens im Hinblick auf die IT-Community vor Ort und seinen wachsenden Kundenstamm in den Benelux-Staaten. Im Rahmen dieser Unterstützung sponsert NTT Com auch MORE-IP, ein Networking-Event für die Internetbranche, das in Amsterdam stattfindet. Ausgerichtet wird die Veranstaltung von dem nichtkommerziellen AMS-IX (Amsterdam Internet Exchange), einem der weltweit größten Internet-Knoten mit Standorten im Großraum Amsterdam und im Science Park. "Die Niederlande spielen bei der weltweiten digitalen Infrastruktur, die immer dichter und kapazitätsstärker wird, eine strategische Rolle. Diese Expansion stellt für NTT Com einen wichtigen Beitrag zu seiner Entwicklung sowohl in den Niederlanden als auch weltweit dar", so Jesse Robbers, CCO, AMS-IX. Das durchweg unter die besten Netzwerke der Welt gewählte globale Tier-1-IP-Netzwerk von NTT Com deckt Nord- und Südamerika, Asien, Europa und Ozeanien ab und bietet die bestmögliche Umgebung für den Transport von Inhalten, Daten und Videos über eine einzige autonome Systemnummer (AS 2914). Laut dem neuesten Dyn Wholesale Ranking ist NTT Com einer der besten IP-Wholesale-Anbieter und darüber hinaus der führende Anbieter in Asien.


News Article | May 22, 2017
Site: www.prnewswire.co.uk

The new PoP is located in the Interxion (formerly Vancis) data center building in Amsterdam Science Park. It is NTT Com's third location in the city and reflects the company's commitment to the local IT community and its growing Benelux customer base. In addition to the Interxion building, the PoP will cross connect with Digital Realty, SURFsara and the National Institute for Subatomic Physics (Nikhef). Customers will have access to NTT Com's Global IP Network and its IP transit services, Layer 2 Ethernet solutions and DDoS Protection Services. "NTT Com is focused on anticipating user demand and has identified Amsterdam Science Park as a world-class hub for research, innovation and entrepreneurship. We are delighted to be supporting such a vibrant, leading-edge community," commented Toby Russell, Sales Director, NTT Europe. As part of this support, NTT Com is also sponsoring MORE-IP, a networking event for the internet industry taking place in Amsterdam. It is hosted by non-profit AMS-IX (Amsterdam Internet Exchange), one of the world's largest internet exchanges with locations in the greater Amsterdam area and also at the Science Park. "The Netherlands plays a strategic role in the global digital infrastructure, which is growing in density and capacity. With this expansion, NTT Com is making an important contribution to its evolution both in the Netherlands and worldwide," said Jesse Robbers, CCO, AMS-IX. NTT Communications provides consultancy, architecture, security and cloud services to optimize the information and communications technology (ICT) environments of enterprises. These offerings are backed by the company's worldwide infrastructure, including leading global tier-1 IP network, Arcstar Universal One™ VPN network reaching 196 countries/regions, and over 140 secure data centers worldwide. NTT Communications' solutions leverage the global resources of NTT Group companies including Dimension Data, NTT DOCOMO and NTT DATA. Consistently ranked among the top networks worldwide, NTT Com's Tier-1 Global IP Network covers North and South America, Asia, Europe and Oceania, and provides the best possible environment for content, data and video transport through a single autonomous system number (AS 2914). NTT Com is one of the top global wholesale IP providers and the number one provider in Asia according to the latest Dyn Wholesale Rankings. More information in Europe, Middle East and Africa: http://www.eu.ntt.com | Twitter @NTT Europe US and the Americas: http://www.us.ntt.net | Twitter @NTT_America (in English) | @NTTComLatam (in Spanish and Portuguese) #globalipnetwork #AS2914


New PoP is Located at One of Europe’s Largest Hubs for Science Education, Research and Entrepreneurship LONDON, 22-May-2017 — /EuropaWire/ — NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group, announced today that it has expanded its Tier-1 Global IP Network with a new Point of Presence (PoP) at the Amsterdam Science Park. The site is home to a host of prestigious educational institutions, cutting-edge research units and knowledge-intensive multinationals and start-ups. The new PoP is located in the Interxion (formerly Vancis) data center building in Amsterdam Science Park. It is NTT Com’s third location in the city and reflects the company’s commitment to the local IT community and its growing Benelux customer base. In addition to the Interxion building, the PoP will cross connect with Digital Realty, SURFsara and the National Institute for Subatomic Physics (Nikhef). Customers will have access to NTT Com’s Global IP Network and its IP transit services, Layer 2 Ethernet solutions and DDoS Protection Services. “NTT Com is focused on anticipating user demand and has identified Amsterdam Science Park as a world-class hub for research, innovation and entrepreneurship. We are delighted to be supporting such a vibrant, leading-edge community,” commented Toby Russell, Sales Director, NTT Europe. As part of this support, NTT Com is also sponsoring MORE-IP, a networking event for the internet industry taking place in Amsterdam. It is hosted by non-profit AMS-IX (Amsterdam Internet Exchange), one of the world’s largest internet exchanges with locations in the greater Amsterdam area and also at the Science Park. “The Netherlands plays a strategic role in the global digital infrastructure, which is growing in density and capacity. With this expansion, NTT Com is making an important contribution to its evolution both in the Netherlands and worldwide,” said Jesse Robbers, CCO, AMS-IX. About NTT Communications Corporation NTT Communications provides consultancy, architecture, security and cloud services to optimize the information and communications technology (ICT) environments of enterprises. These offerings are backed by the company’s worldwide infrastructure, including leading global tier-1 IP network, Arcstar Universal One™ VPN network reaching 196 countries/regions, and over 140 secure data centers worldwide. NTT Communications’ solutions leverage the global resources of NTT Group companies including Dimension Data, NTT DOCOMO and NTT DATA. About NTT Communications Global IP Network Consistently ranked among the top networks worldwide, NTT Com’s Tier-1 Global IP Network covers North and South America, Asia, Europe and Oceania, and provides the best possible environment for content, data and video transport through a single autonomous system number (AS 2914). NTT Com is one of the top global wholesale IP providers and the number one provider in Asia according to the latest Dyn Wholesale Rankings. More information in Europe, Middle East and Africa: www.eu.ntt.com | Twitter @NTT Europe US and the Americas: www.us.ntt.net | Twitter @NTT_America (in English) | @NTTComLatam (in Spanish and Portuguese) #globalipnetwork #AS2914


The new PoP is located in the Interxion (formerly Vancis) data center building in Amsterdam Science Park. It is NTT Com's third location in the city and reflects the company's commitment to the local IT community and its growing Benelux customer base. In addition to the Interxion building, the PoP will cross connect with Digital Realty, SURFsara and the National Institute for Subatomic Physics (Nikhef). Customers will have access to NTT Com's Global IP Network and its IP transit services, Layer 2 Ethernet solutions and DDoS Protection Services. "NTT Com is focused on anticipating user demand and has identified Amsterdam Science Park as a world-class hub for research, innovation and entrepreneurship. We are delighted to be supporting such a vibrant, leading-edge community," commented Toby Russell, Sales Director, NTT Europe. As part of this support, NTT Com is also sponsoring MORE-IP, a networking event for the internet industry taking place in Amsterdam. It is hosted by non-profit AMS-IX (Amsterdam Internet Exchange), one of the world's largest internet exchanges with locations in the greater Amsterdam area and also at the Science Park. "The Netherlands plays a strategic role in the global digital infrastructure, which is growing in density and capacity. With this expansion, NTT Com is making an important contribution to its evolution both in the Netherlands and worldwide," said Jesse Robbers, CCO, AMS-IX. NTT Communications provides consultancy, architecture, security and cloud services to optimize the information and communications technology (ICT) environments of enterprises. These offerings are backed by the company's worldwide infrastructure, including leading global tier-1 IP network, Arcstar Universal One™ VPN network reaching 196 countries/regions, and over 140 secure data centers worldwide. NTT Communications' solutions leverage the global resources of NTT Group companies including Dimension Data, NTT DOCOMO and NTT DATA. Consistently ranked among the top networks worldwide, NTT Com's Tier-1 Global IP Network covers North and South America, Asia, Europe and Oceania, and provides the best possible environment for content, data and video transport through a single autonomous system number (AS 2914). NTT Com is one of the top global wholesale IP providers and the number one provider in Asia according to the latest Dyn Wholesale Rankings. More information in Europe, Middle East and Africa: http://www.eu.ntt.com | Twitter @NTT Europe US and the Americas: http://www.us.ntt.net | Twitter @NTT_America (in English) | @NTTComLatam (in Spanish and Portuguese) #globalipnetwork #AS2914


- ND0612 head-to-head pilot PK results and ND0701 first-in-man PK results to also be presented - REHOVOT, Israel, May 23, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that complete data from trial 006 will be showcased in a late-breaking poster session at the 21st International Congress of Parkinson’s Disease and Movement Disorders, taking place June 4-8, 2017 in Vancouver, B.C. Trial 006 was an international open label, blinded rater, phase II study of ND0612H, NeuroDerm's high dose continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation, in patients with advanced Parkinson's disease. ND0612 will be featured in five additional abstracts, and data from pharmacokinetic (PK) studies of ND0701 will also be presented. In March 2017, NeuroDerm announced that a preliminary analysis of trial 006 demonstrated that the trial successfully met its primary, key secondary and additional secondary endpoints, with many patients experiencing a complete reduction of OFF-time to zero. Sheila Oren, MD, MBA, Chief Medical Officer at NeuroDerm will present the complete results from this trial in a poster titled, “Safety, efficacy and tolerability of continuous SC LD/CD (ND0612) infusion in PD patients with motor fluctuations,” (Abstract LBA41) in a late-breaking abstract session on Wednesday, June 7, from 1:15 p.m. to 2:45 p.m. PT. Tami Rachmilevitz MD, Medical Director at NeuroDerm will present additional data from trial 006 in an abstract titled, “Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD,” (Abstract 1377) in a poster session on Thursday, June 8, from 1:15 p.m. to 2:45 p.m. PT. Previously unannounced complete results from a head-to-head pilot PK comparison trial (trial 005) evaluating ND0612 and intra-duodenally delivered LD/CD gel suspension requiring surgical intervention (DUODOPA®/DUOPATM) will also be presented by Liat Adar, PhD, Director Clinical Pharmacology and Personalized Medicine at NeuroDerm, in an abstract titled, “Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion,” (Abstract 1337). This abstract will also be presented in the poster session on Thursday, June 8, from 1:15 p.m. to 2:45 p.m. PT.  NeuroDerm reported topline results from this study in June 2016, with topline results demonstrating comparable bioavailability to DUODOPA®. Additionally, Cecile Durach, Medical Director of Europe at NeuroDerm will present first-in-man clinical results for ND0701, the company’s continuous apomorphine product. The abstract, titled, “ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data” (Abstract 1391) will be presented on Thursday, June 8 from 1:15 p.m. to 2:45 p.m. PT. The following abstracts will also be presented during the poster session on Thursday, June 8 from 1:15 p.m. to 2:45 p.m. PT: About NeuroDerm         NeuroDerm is a clinical-stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm has three product candidates in different stages of development that offer a solution for almost every Parkinson’s disease patient from the moderate to the very severe stage of the disease. NeuroDerm has developed a line of levodopa and carbidopa (LD/CD) product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD product candidates are ND0612L and ND0612H, which are used for treatment of moderate and advanced Parkinson’s disease patients, respectively, and which are delivered subcutaneously. In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel. Forward-Looking Statements This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties. Such forward-looking statements may include projections regarding our future performance and may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the risks provided under "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2016 filed with the Securities and Exchange Commission. Any forward-looking statement made by us in this press release speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


- ND0612 head-to-head pilot PK results and ND0701 first-in-man PK results to also be presented - REHOVOT, Israel, May 23, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that complete data from trial 006 will be showcased in a late-breaking poster session at the 21st International Congress of Parkinson’s Disease and Movement Disorders, taking place June 4-8, 2017 in Vancouver, B.C. Trial 006 was an international open label, blinded rater, phase II study of ND0612H, NeuroDerm's high dose continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation, in patients with advanced Parkinson's disease. ND0612 will be featured in five additional abstracts, and data from pharmacokinetic (PK) studies of ND0701 will also be presented. In March 2017, NeuroDerm announced that a preliminary analysis of trial 006 demonstrated that the trial successfully met its primary, key secondary and additional secondary endpoints, with many patients experiencing a complete reduction of OFF-time to zero. Sheila Oren, MD, MBA, Chief Medical Officer at NeuroDerm will present the complete results from this trial in a poster titled, “Safety, efficacy and tolerability of continuous SC LD/CD (ND0612) infusion in PD patients with motor fluctuations,” (Abstract LBA41) in a late-breaking abstract session on Wednesday, June 7, from 1:15 p.m. to 2:45 p.m. PT. Tami Rachmilevitz MD, Medical Director at NeuroDerm will present additional data from trial 006 in an abstract titled, “Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD,” (Abstract 1377) in a poster session on Thursday, June 8, from 1:15 p.m. to 2:45 p.m. PT. Previously unannounced complete results from a head-to-head pilot PK comparison trial (trial 005) evaluating ND0612 and intra-duodenally delivered LD/CD gel suspension requiring surgical intervention (DUODOPA®/DUOPATM) will also be presented by Liat Adar, PhD, Director Clinical Pharmacology and Personalized Medicine at NeuroDerm, in an abstract titled, “Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion,” (Abstract 1337). This abstract will also be presented in the poster session on Thursday, June 8, from 1:15 p.m. to 2:45 p.m. PT.  NeuroDerm reported topline results from this study in June 2016, with topline results demonstrating comparable bioavailability to DUODOPA®. Additionally, Cecile Durach, Medical Director of Europe at NeuroDerm will present first-in-man clinical results for ND0701, the company’s continuous apomorphine product. The abstract, titled, “ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data” (Abstract 1391) will be presented on Thursday, June 8 from 1:15 p.m. to 2:45 p.m. PT. The following abstracts will also be presented during the poster session on Thursday, June 8 from 1:15 p.m. to 2:45 p.m. PT: About NeuroDerm         NeuroDerm is a clinical-stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm has three product candidates in different stages of development that offer a solution for almost every Parkinson’s disease patient from the moderate to the very severe stage of the disease. NeuroDerm has developed a line of levodopa and carbidopa (LD/CD) product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD product candidates are ND0612L and ND0612H, which are used for treatment of moderate and advanced Parkinson’s disease patients, respectively, and which are delivered subcutaneously. In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel. Forward-Looking Statements This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties. Such forward-looking statements may include projections regarding our future performance and may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the risks provided under "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2016 filed with the Securities and Exchange Commission. Any forward-looking statement made by us in this press release speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


- ND0612 head-to-head pilot PK results and ND0701 first-in-man PK results to also be presented - REHOVOT, Israel, May 23, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that complete data from trial 006 will be showcased in a late-breaking poster session at the 21st International Congress of Parkinson’s Disease and Movement Disorders, taking place June 4-8, 2017 in Vancouver, B.C. Trial 006 was an international open label, blinded rater, phase II study of ND0612H, NeuroDerm's high dose continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation, in patients with advanced Parkinson's disease. ND0612 will be featured in five additional abstracts, and data from pharmacokinetic (PK) studies of ND0701 will also be presented. In March 2017, NeuroDerm announced that a preliminary analysis of trial 006 demonstrated that the trial successfully met its primary, key secondary and additional secondary endpoints, with many patients experiencing a complete reduction of OFF-time to zero. Sheila Oren, MD, MBA, Chief Medical Officer at NeuroDerm will present the complete results from this trial in a poster titled, “Safety, efficacy and tolerability of continuous SC LD/CD (ND0612) infusion in PD patients with motor fluctuations,” (Abstract LBA41) in a late-breaking abstract session on Wednesday, June 7, from 1:15 p.m. to 2:45 p.m. PT. Tami Rachmilevitz MD, Medical Director at NeuroDerm will present additional data from trial 006 in an abstract titled, “Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD,” (Abstract 1377) in a poster session on Thursday, June 8, from 1:15 p.m. to 2:45 p.m. PT. Previously unannounced complete results from a head-to-head pilot PK comparison trial (trial 005) evaluating ND0612 and intra-duodenally delivered LD/CD gel suspension requiring surgical intervention (DUODOPA®/DUOPATM) will also be presented by Liat Adar, PhD, Director Clinical Pharmacology and Personalized Medicine at NeuroDerm, in an abstract titled, “Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion,” (Abstract 1337). This abstract will also be presented in the poster session on Thursday, June 8, from 1:15 p.m. to 2:45 p.m. PT.  NeuroDerm reported topline results from this study in June 2016, with topline results demonstrating comparable bioavailability to DUODOPA®. Additionally, Cecile Durach, Medical Director of Europe at NeuroDerm will present first-in-man clinical results for ND0701, the company’s continuous apomorphine product. The abstract, titled, “ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data” (Abstract 1391) will be presented on Thursday, June 8 from 1:15 p.m. to 2:45 p.m. PT. The following abstracts will also be presented during the poster session on Thursday, June 8 from 1:15 p.m. to 2:45 p.m. PT: About NeuroDerm         NeuroDerm is a clinical-stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm has three product candidates in different stages of development that offer a solution for almost every Parkinson’s disease patient from the moderate to the very severe stage of the disease. NeuroDerm has developed a line of levodopa and carbidopa (LD/CD) product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD product candidates are ND0612L and ND0612H, which are used for treatment of moderate and advanced Parkinson’s disease patients, respectively, and which are delivered subcutaneously. In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel. Forward-Looking Statements This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties. Such forward-looking statements may include projections regarding our future performance and may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the risks provided under "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2016 filed with the Securities and Exchange Commission. Any forward-looking statement made by us in this press release speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


- ND0612 head-to-head pilot PK results and ND0701 first-in-man PK results to also be presented - REHOVOT, Israel, May 23, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that complete data from trial 006 will be showcased in a late-breaking poster session at the 21st International Congress of Parkinson’s Disease and Movement Disorders, taking place June 4-8, 2017 in Vancouver, B.C. Trial 006 was an international open label, blinded rater, phase II study of ND0612H, NeuroDerm's high dose continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation, in patients with advanced Parkinson's disease. ND0612 will be featured in five additional abstracts, and data from pharmacokinetic (PK) studies of ND0701 will also be presented. In March 2017, NeuroDerm announced that a preliminary analysis of trial 006 demonstrated that the trial successfully met its primary, key secondary and additional secondary endpoints, with many patients experiencing a complete reduction of OFF-time to zero. Sheila Oren, MD, MBA, Chief Medical Officer at NeuroDerm will present the complete results from this trial in a poster titled, “Safety, efficacy and tolerability of continuous SC LD/CD (ND0612) infusion in PD patients with motor fluctuations,” (Abstract LBA41) in a late-breaking abstract session on Wednesday, June 7, from 1:15 p.m. to 2:45 p.m. PT. Tami Rachmilevitz MD, Medical Director at NeuroDerm will present additional data from trial 006 in an abstract titled, “Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD,” (Abstract 1377) in a poster session on Thursday, June 8, from 1:15 p.m. to 2:45 p.m. PT. Previously unannounced complete results from a head-to-head pilot PK comparison trial (trial 005) evaluating ND0612 and intra-duodenally delivered LD/CD gel suspension requiring surgical intervention (DUODOPA®/DUOPATM) will also be presented by Liat Adar, PhD, Director Clinical Pharmacology and Personalized Medicine at NeuroDerm, in an abstract titled, “Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion,” (Abstract 1337). This abstract will also be presented in the poster session on Thursday, June 8, from 1:15 p.m. to 2:45 p.m. PT.  NeuroDerm reported topline results from this study in June 2016, with topline results demonstrating comparable bioavailability to DUODOPA®. Additionally, Cecile Durach, Medical Director of Europe at NeuroDerm will present first-in-man clinical results for ND0701, the company’s continuous apomorphine product. The abstract, titled, “ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data” (Abstract 1391) will be presented on Thursday, June 8 from 1:15 p.m. to 2:45 p.m. PT. The following abstracts will also be presented during the poster session on Thursday, June 8 from 1:15 p.m. to 2:45 p.m. PT: About NeuroDerm         NeuroDerm is a clinical-stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm has three product candidates in different stages of development that offer a solution for almost every Parkinson’s disease patient from the moderate to the very severe stage of the disease. NeuroDerm has developed a line of levodopa and carbidopa (LD/CD) product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD product candidates are ND0612L and ND0612H, which are used for treatment of moderate and advanced Parkinson’s disease patients, respectively, and which are delivered subcutaneously. In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel. Forward-Looking Statements This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties. Such forward-looking statements may include projections regarding our future performance and may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the risks provided under "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2016 filed with the Securities and Exchange Commission. Any forward-looking statement made by us in this press release speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Loading Science Park collaborators
Loading Science Park collaborators